Jeffrey Wiezorek
Fondateur chez Appia Bio, Inc.
Postes actifs de Jeffrey Wiezorek
Sociétés | Poste | Début | Fin |
---|---|---|---|
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Directeur/Membre du Conseil | 01/01/2020 | - |
Directeur Technique/Scientifique/R&D | 01/01/2020 | - | |
Fondateur | 01/01/2020 | - |
Historique de carrière de Jeffrey Wiezorek
Anciens postes connus de Jeffrey Wiezorek
Sociétés | Poste | Début | Fin |
---|---|---|---|
AMGEN INC. | Corporate Officer/Principal | 01/10/2009 | 01/04/2014 |
KITE PHARMA INC | Directeur Technique/Scientifique/R&D | 12/05/2014 | - |
Corporate Officer/Principal | 12/05/2014 | - |
Formation de Jeffrey Wiezorek
University of Pennsylvania | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AMGEN INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Bourse
- Insiders
- Jeffrey Wiezorek
- Expérience